Myriad Genetics Inc (MYGN.OQ)
25 Jul 2014
|Market Cap (Mil.):||$2,794.67|
|Shares Outstanding (Mil.):||74.82|
HONG KONG, June 12 - Betting on a weaker Chinese currency is the best way for investors to protect an equity portfolio as China enters a protracted period of slowing growth, said Carl Huttenlocher, chief investment officer of Myriad Asset Management.
NEW YORK, March 11 - U.S. stocks were little changed on Tuesday as investors found few reasons to push the S&P 500 above its recent record high, as tensions in Ukraine continued.
NEW YORK, March 11 - U.S. stocks were set for a flat open on Tuesday after a slight decline in the prior session left the S&P 500 within striking distance of its recent record high and amid investor caution as tensions in Ukraine continued.
- Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad's gene-based cancer test, the latest setback for the diagnostics company.
March 11 - Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad's gene-based cancer test, the latest setback for the diagnostics company.
* Futures: Dow off 8 pts, S&P off 1.25 pt, Nasdaq up 0.25 pt
March 11 - Diagnostics company Myriad Genetics Inc said a U.S. court denied a motion that would have stopped rival Ambry Genetics Corp from selling a similar version of Myriad's cancer test.
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s) U.S. stock index futures were little changed on Wednesday. Dow Jones industrial average futures were down 0.07 percent at 15,328, S&P 500 futures were down 0.17 percent at 1,740.7 and Nasdaq 100 futures were down 0.03 percent at 3,451.
- Molecular diagnostics company Myriad Genetics Inc said it plans to buy Crescendo Bioscience for $270 million to enter the autoimmune market, and raised its full-year forecast.
Feb 4 - Molecular diagnostics company Myriad Genetics Inc said it plans to buy Crescendo Bioscience for $270 million to enter the autoimmune market, and raised its full-year forecast.
|Johnson & Johnson (JNJ.N)||$102.11||-0.09|
|Abbott Laboratories (ABT.N)||$43.04||+0.15|
|Bristol-Myers Squibb Co (BMY.N)||$49.39||-0.07|
|Bristol-Myers Squibb Co (BMYMP.PK)||$829.72||-58.28|
|Amgen, Inc. (AMGN.OQ)||$122.84||+0.58|
|Monsanto Company (MON.N)||$115.79||-0.40|
|Merck KGaA (MRCG.DE)||€64.38||-1.05|
|Gilead Sciences, Inc. (GILD.OQ)||$89.84||-0.70|
|Mylan Inc (MYL.OQ)||$51.74||-0.16|
|Allergan, Inc. (AGN.N)||$170.06||-0.51|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of MYRIAD GENETICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
"The Economy Matters" Report for MYGN: the economy's impact on MYGN's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.